Cardiology management improves secondary prevention measures among patients with coronary artery disease  by Ho, P.Michael et al.
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OBJECTIVES The goal of this study was to determine if cardiology subspecialty involvement improves the
attainment of recommended low-density lipoprotein (LDL) cholesterol and blood pressure
(BP) targets in coronary artery disease (CAD) patients.
BACKGROUND The impact of physician specialty on secondary prevention measures for CAD in ambulatory
care is unknown.
METHODS This was a retrospective cohort study of 13,995 patients with CAD seen at eight ambulatory
care Veteran Affairs facilities from 1998 to 2000. Patients with cardiology involvement were
defined as those seen in cardiology clinic in addition to primary care. The main outcomes of
interest were LDL cholesterol 100 mg/dl and BP 130/85 mm Hg. Multivariable
hierarchical regression analyses were used to determine the independent association of
cardiology involvement with improved LDL cholesterol and BP control.
RESULTS Overall, 3,771 (27.0%) patients had cardiology involvement. A higher proportion of patients
with cardiology involvement achieved LDL cholesterol (55.6% vs. 45.6%; p  0.01) and BP
(45.3% vs. 35.9%; p 0.01) goals. In multivariable hierarchical regression analysis, cardiology
involvement was independently associated with better LDL cholesterol (odds ratio [OR],
1.59; 95% confidence interval [CI], 1.40 to 1.82) and BP (OR, 1.52; 95% CI, 1.32 to 1.77)
control. The benefit of cardiology involvement was consistent across a range of LDL and BP
targets, in analysis of LDL and BP as continuous outcomes, and among subgroups of
high-risk patients, including diabetic patients, the elderly, and those with prior revascular-
ization.
CONCLUSIONS Cardiology involvement is associated with better LDL cholesterol and BP control among
CAD patients. However, significant room for improvement in secondary prevention measures
remains, irrespective of physician specialty. (J Am Coll Cardiol 2004;43:1517–23) © 2004
by the American College of Cardiology Foundations
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sn order to reduce the morbidity and mortality of the 12
illion patients in the U.S. with coronary artery disease
CAD), aggressive secondary prevention measures, includ-
ng low-density lipoprotein (LDL) cholesterol reduction
nd blood pressure (BP) control have been strongly recom-
ended by multiple national guidelines (1–4). The Amer-
can College of Cardiology/American Heart Association
uidelines have established targets for treatment of LDL
holesterol at 100 mg/dl and BP at 130/85 mm Hg for
atients with established CAD (4). Despite the strong
vidence supporting these recommendations and the wide-
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argets have been suboptimal (5–9).
Prior studies have found that some measures of quality of
are and outcomes for patients with cardiovascular disease
ay differ by the specialty of the caring physician (10–16).
pecifically, patients hospitalized with acute myocardial
nfarction (AMI) who were treated by cardiologists were
ore likely to receive thrombolytics, aspirin, and beta-
lockers and to have lower mortality rates compared with
hose treated by generalist physicians. Additionally, Aya-
ian et al. (14) recently found that cardiology specialty of
mbulatory care physicians was associated with decreased
wo-year mortality among elderly patients after a myocardial
nfarction. One possible explanation for this observed sur-
ival advantage with subspecialty care is that cardiologists
re more aggressive in treating risk factors. These risk
actors, including hyperlipidemia, hypertension, diabetes,
nd smoking are present in over 80% of CAD patients (17).
o our knowledge, the association between cardiology
pecialty management and guideline adherence for second-
ry prevention measures has not been studied. Accordingly,
he objective of this study was to determine if cardiology
ubspecialty involvement in ambulatory chronic care of
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Cardiology Management and Secondary Prevention May 5, 2004:1517–23AD patients is associated with improved LDL cholesterol
nd BP control in a multi-center cohort of CAD patients.
ETHODS
tudy population. All active patients with CAD enrolled
n primary care clinics in any one of eight Pacific Northwest
eterans Affairs (VA) hospital facilities were included in the
tudy. Patients with CAD were identified by any one or
ore of the following International Classification of
iseases-9th revision (ICD-9) diagnosis codes in the 24
onths before the index date: 410.x, 411.x, 412, or 414.x.
e searched for these diagnosis codes in the active problem
ist file of the VA computerized medical record, the outpa-
ient care (OPC) file, and the patient treatment file (PTF)
6). The OPC file contains data on all outpatient visits,
hereas the PTF file contains data on all in-patient encoun-
ers. These files are part of the Consumer Health Informa-
ion & Performance Sets (CHIPS) Data Warehouse, which
s a relational database mirroring the clinical information
ystem residing at each VA Medical Center and outpatient
acility (18).
Active patients were defined as being alive on October 1,
000 (index date), and having at least one primary care
linic visit documented in the OPC file per year in each of
he two previous years. A primary care visit was defined
sing the OPC file as any visit to one or more of the
ollowing clinics: General Internal Medicine, Women’s
linic, Primary Care/Medicine, or Geriatrics. Patients were
efined as having cardiology involvement if they had at least
ne cardiology clinic visit anytime during the 24 months
efore the index date.
ndependent variables. Clinical characteristics were de-
ned by ICD-9 codes within either the OPC and/or PTF
les within the 24 months before the index date: percuta-
eous coronary intervention (PCI), coronary artery bypass
raft (CABG) surgery, diabetes, hypertension, hyperlipid-
mia, chronic obstructive pulmonary disease, peripheral
ascular disease, cerebrovascular disease, congestive heart
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ACS  acute coronary syndrome
AMI  acute myocardial infarction
BP  blood pressure
CABG  coronary artery bypass graft
CAD  coronary artery disease
CI  confidence interval
ICD-9  International Classification of Diseases-
9th revision
LDL  low-density lipoprotein
OPC  outpatient care file
OR  odds ratio
PCI  percutaneous coronary intervention
PTF  patient treatment file
VA  Veterans Affairsailure, depression, and renal disease. tRecent hospital admission for an acute coronary syn-
rome (ACS) and recent coronary revascularization proce-
ure(s) (i.e., PCI and/or CABG) were defined as occurring
ithin the 15 months before the index date. Hospital
dmission for ACS was defined by a primary discharge
iagnosis of ICD-9 codes 410.x or 411.x in the PTF file.
he number of outpatient clinic visits was aggregated over
he 15 months before the index date.
Patients were defined as having a current medication
rescription for the following classes of medications if they
ad a prescription written or renewed within the last 15
onths before the index date: beta-blockers, angiotensin-
onverting enzyme (ACE) inhibitors or angiotensin recep-
or blockers, calcium channel blockers, diuretics, and
-hydroxy-3-methylglutaryl coenzyme-A reductase inhibi-
ors (statins).
Facility level data were obtained from the Veterans
ntegrated Service Network Support Service Center web-
ite, a health care information and technical support orga-
ization serving the needs of the networks (19). Data on
olume of primary care patients and visits were obtained for
ach of the eight facilities included in the analysis.
utcome variables. The two primary outcomes of interest
ere achievement of: 1) LDL 100 mg/dl; and 2) BP
130/85 mm Hg, consistent with national guidelines as
reatment targets for patients with underlying CAD (4).
ny lipid level measured within 15 months before the index
ate was included, and the most current LDL level was used
n the analyses. An LDL measurement was available for
3.6% of the patients. All patients had at least one BP
easurement within the six months before the index date.
mong the 68.8% of patients with two or more BP
easurements, the BP readings were averaged.
tatistical analysis. We compared baseline patient charac-
eristics and processes of care (e.g., number of clinic visits
nd prescribed medications) between patients with cardiol-
gy involvement and patients without cardiology involve-
ent, using t tests for continuous variables and the chi-
quare tests for categorical variables. Next, we evaluated
chievement of secondary prevention goals between patients
ith and without cardiology involvement using two differ-
nt LDL cholesterol (i.e., LDL 100 mg/dl and 130
g/dl) and BP (i.e., 130/85 mm Hg and 140/90 mm
g) treatment targets. Then, we compared the mean LDL
holesterol, mean systolic BP, and mean diastolic BP
etween the two groups.
In order to determine if cardiology involvement was
ndependently associated with improved LDL and BP
ontrol compared with no cardiology involvement, we first
onstructed a series of patient-level multivariable logistic
egression models. Variables that were significantly different
etween the cardiology involvement and the no cardiology
nvolvement groups (p  0.10) were candidates for the risk
odels. A baseline risk model was constructed consisting of
atient demographics, medical history, number of days from
he last LDL or BP measurement, recent ACS event or
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May 5, 2004:1517–23 Cardiology Management and Secondary Preventionoronary revascularization procedures, and the number of
linic visits. These outpatient visits were also analyzed
eparately as primary care clinic visits only, cardiology clinic
isits only, and primary care plus cardiology clinic visits. In
ddition, we fitted a separate logistic regression model to
stimate the propensity that a patient would have a cardi-
logy clinic visit and included the propensity score as an
ndependent predictor variable in the baseline risk model
20). Then, the cardiology involvement variable was added
o the risk model to determine its independent association
ith the outcome. Separate risk models were constructed for
chievement of LDL 100 mg/dl and BP 130/85 mm
g. To assess whether there was a “dose-response” associ-
tion between the number of cardiology clinic visits and
DL or BP control, we fitted logistic regression models in
hich the number of cardiology clinic visits was categorized
nto quartiles.
Next, to account for the clustering of patients within
roviders and facilities, hierarchical regression models were
onstructed using NLMIXED in SAS (Version 8.02, SAS
nstitute, Cary, North Carolina). The cardiology involve-
ent variable was entered into the model, adjusting for
atient-level risk factors (i.e., all patient-level variables
ssociated with either of the outcomes in the baseline risk
odels) and clustering of patients within providers and
acilities to determine its independent association with LDL
nd BP control. Subsequent models also adjusted for other
acility characteristics such as tertiary versus primary care
Table 1. Baseline Characteristics of Coronary
Cardiology Involvement
Variables
Age, mean (SD)
Male gender
Married
White
Obese (body mass index 30 m2/kg)
Congestive heart failure
Prior myocardial infarction
Diabetes
Hypertension
Hyperlipidemia
Prior percutaneous coronary intervention
Prior coronary artery bypass graft surgery
Chronic obstructive pulmonary disease
Cerebrovascular disease
Depression
Peripheral vascular disease
Renal disease
Coronary revascularization within last 15 months
Acute coronary syndrome within last 15 months
Total clinic visits over 15 months, mean (SD)
Number of prescribed medications, mean (SD)
Number of co-morbidities,* mean (SD)
*Number of co-morbidities  obesity  congestive heart
obstructive pulmonary disease  cerebrovascular disease  dacility and primary care clinic volume as defined by both 2he number of clinic visits and the number of patients
nrolled.
econdary analyses. We performed sensitivity analyses to
etermine if the observed relationship between cardiology
nvolvement and improved LDL and BP control was
ignificant when different definitions for the outcome vari-
bles were applied. Using similar multivariable regression
odeling techniques, we redefined the outcomes for LDL
holesterol and BP as 130 mg/dl and 140/90 mm Hg,
espectively, and evaluated the independent association
etween cardiology involvement and achievement of these
ew targets. Next, we analyzed LDL cholesterol, systolic
P, and diastolic BP as continuous outcome variables in
ultivariable linear regression models, adjusting for patient
o-morbidities and processes of care. Finally, to determine if
he benefit of cardiology involvement was consistent across
ifferent high-risk subgroups, we evaluated this relationship
n older patients (age 65 years), diabetics, and those with
rior coronary revascularization (i.e., PCI or CABG). All
nalyses were performed using SAS (Version 8.02, SAS
nstitute). The study was approved by the Colorado Mul-
iple Institutional Review Board.
ESULTS
able 1 compares the baseline characteristics of patients
ith and without cardiology involvement. Of 13,955 active
AD patients in the Pacific Northwest VA facilities, 3,771
27.0%) patients had at least one cardiology clinic visit and
y Disease Patients With and Without
Cardiology
nvolvement
n  3,771)
No Cardiology
Involvement
(n  10,184) p Value
6.8  10.7 68.6  10.4  0.01
97.8 97.8 0.85
56.9 59.1 0.02
84.7 85.5 0.26
44.0 42.4 0.09
36.4 15.2  0.01
16.5 9.0  0.01
38.2 33.8  0.01
78.5 69.1  0.01
61.6 53.6  0.01
16.3 6.3  0.01
31.5 17.1  0.01
35.2 27.9  0.01
15.2 9.4  0.01
10.7 6.8  0.01
12.8 11.0  0.01
8.8 5.0  0.01
11.2 0.6  0.01
10.5 1.3  0.01
12.4  8.6 7.4  5.8  0.01
11.9  6.2 11.0  5.9  0.01
3.4  1.6 2.7  1.4  0.01
 diabetes  hypertension  hyperlipidemia  chronic
ion  peripheral vascular disease  renal disease.Arter
I
(
6
failure,177 (15.6%) had at least two or more visits. Patients with
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Cardiology Management and Secondary Prevention May 5, 2004:1517–23ardiology involvement were younger, but a greater propor-
ion had cardiac co-morbidities including hypertension,
iabetes, hyperlipidemia, prior myocardial infarction, and
rior coronary revascularization. Cardiology involvement
atients also had a higher burden of non-cardiac co-
orbidities including chronic obstructive pulmonary disease
nd depression. A greater proportion of cardiology involve-
ent patients experienced a recent ACS event or coronary
evascularization procedure, and they also had more overall
linic visits.
In unadjusted analyses, patients with cardiology involve-
ent were more likely to achieve LDL cholesterol and BP
argets as recommended by national guidelines (Fig. 1).
urthermore, patients with cardiology involvement had
ower mean systolic BPs (134.2  17.4 mm Hg vs. 138.9 
8.6 mm Hg; p 0.01), lower mean diastolic BPs (71.2 
0.1 mm Hg vs. 74.1  10.7 mm Hg; p 0.01), and lower
igure 1. Proportion of coronary artery disease patients meeting low-
ensity lipoprotein (LDL) cholesterol and blood pressure (BP) goals. *p 
.01. Open bars  no cardiology involvement; solid bars  cardiology
nvolvement.Figure 2. Subgroup analysis. BP  blood pressure; DM ean LDL cholesterol (99.8 32.0 mg/dl vs. 107.8 34.7
g/dl; p0.01) compared with patients without cardiology
nvolvement. This observed benefit with cardiology involve-
ent remained consistent among subgroups of older pa-
ients, diabetics, and those with prior coronary revascular-
zation (Fig. 2). Patients with cardiology involvement were
lso more likely to be prescribed beta-blockers, ACE
nhibitors, or angiotensin receptor blockers and diuretics
Fig. 3). Furthermore, there was a dose-response relation-
hip between the number of cardiology clinic visits and the
dds of having LDL or BP treated to guideline recommen-
ations.
In multivariable hierarchical regression models, cardiol-
igure 3. Proportion of coronary artery disease patients with and without
ardiology involvement prescribed the following classes of medications.
CEi  angiotensin-converting enzyme inhibitor; ARB  angiotensin
eceptor blockers; CCB  calcium channel blocker. *p  0.01. Open bars
no cardiology involvement; solid bars  cardiology involvement.diabetes mellitus; LDL  low-density lipoprotein.
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May 5, 2004:1517–23 Cardiology Management and Secondary Preventiongy involvement was independently associated with better
DL control (odds ratio [OR], 1.59; 95% confidence
nterval [CI], 1.40 to 1.82) and BP control (OR, 1.52; 95%
I, 1.32 to 1.77) after adjusting for patient demographics,
edical history, number of clinic visits, recent ACS or
oronary revascularization procedure, number of days from
ast LDL or BP measurement, propensity to have a cardi-
logy visit, and clustering of patients within providers and
acilities. The magnitude of benefit for cardiology involve-
ent remained unchanged in subsequent risk models that
lso adjusted for tertiary care facility and primary care clinic
olume and when less stringent guideline targets were used
o define the outcomes (i.e., 130 mg/dl for LDL choles-
erol and 140/90 mm Hg for BP).
When the outcomes were analyzed as continuous vari-
bles in multivariable linear regression analyses, cardiology
nvolvement was associated with lower systolic BP (2.70
0.38 mm Hg; p 0. 01), lower diastolic BP (1.97 
.23 mm Hg; p0. 01), and lower LDL cholesterol (5.82
0.74 mg/dl; p 0.01) even after adjustment for patient
haracteristics and processes of care.
OMMENTS
he primary goal of this study was to determine if cardiol-
gy subspecialty involvement in ambulatory care improves
econdary prevention guideline concordance, specifically
DL cholesterol and BP control, in CAD patients. We
ound that cardiology involvement (i.e., patients seen in
ardiology in addition to primary care) was independently
ssociated with improved LDL and BP control. This
bserved benefit with cardiology involvement remained
ignificant when different targets for LDL and BP were
sed, when LDL and BP were analyzed as continuous
utcome variables, and among subgroups of high-risk pa-
ients.
Based on epidemiologic studies, even small decreases in
DL and BP levels translate into significant reductions in
orbidity and mortality, with a linear relationship between
erum cholesterol or BP and subsequent cardiovascular
vents (21–25). Law et al. (21) estimated that a 10%
ecrease in the serum cholesterol concentration was associ-
ted with a reduction in cardiovascular events of at least 19%
nd as high as 54%, depending on the patient population.
an den Hoogen et al. (24) estimated that the risk of death
ue to CAD was 1.17 per 10 mm Hg increase in systolic BP
nd 1.13 per 5 mm Hg increase in diastolic BP. The lower
evels of LDL cholesterol (8.0 mg/dl or 7% lower),
ystolic BP (4.7 mm Hg), and diastolic BP (2.9 mm
g) associated with cardiology involvement in this study
ould, thus, translate into significant reductions in morbid-
ty and mortality if extrapolated on a population-wide basis.
Recent studies suggest that hyperlipidemia and hyperten-
ion are prevalent conditions among patients with CAD.
hot et al. (17) demonstrated that 80% to 90% of patients
ith CAD have at least one of the four conventional cardiac tisk factors (i.e., hypertension, hyperlipidemia, smoking,
nd diabetes) with hyperlipidemia and hypertension being
he two most common risk factors. Furthermore, Greenland
t al. (26) noted that at least one of these risk factors was
resent in 87% to 100% of patients who subsequently have
fatal cardiovascular event. These studies emphasize the
rgent need to identify and aggressively treat these risk
actors, especially among patients with preexisting CAD
ho have a five-fold to sevenfold increased risk of recurrent
yocardial infarction compared with the general population
27).
Prior studies evaluating the association between physician
pecialty and outcomes of patient’s with CAD have focused
ainly on the hospital setting. Among patients with AMI,
ardiologists were more likely to prescribe guideline-
ndicated therapies, such as thrombolytics, aspirin, and
eta-blockers and to refer patients for revascularization
10–13). In addition, treatment by a cardiologist during
ospitalization for AMI has been associated with lower
n-hospital and one-year mortality (28,14). Although AMI
atients are an important component of the CAD popula-
ion, the majority of CAD patients receive care in the
mbulatory care setting, where less is known about the
ssociation between physician specialty and outcomes of
are.
This study suggests that cardiology subspecialty involve-
ent can have an impact on chronic ambulatory care in
ddition to hospital care. A prior single-centered study
ound improved guideline compliance with LDL goals
mong patients with cardiology involvement (29). In addi-
ion, ambulatory visits to cardiologists have previously been
ssociated with greater use of cardiac procedures and de-
reased mortality after myocardial infarction (14). Although
he greater use of cardiac procedures and revascularization
ay explain, in part, the mortality difference, other factors
uch as LDL and BP control are as important in reducing
ecurrent cardiac events. In this study, CAD patients
anaged with cardiology involvement were more likely to
ave their LDL cholesterol and BP treated to levels recom-
ended by national guidelines despite having more cardiac
nd non-cardiac co-morbidities. Furthermore, we found
hat patients with cardiology involvement were more likely
o receive beta-blockers and ACE inhibitors, therapies that
ave demonstrated survival benefits for CAD patients
30,31).
Our findings suggest that a collaborative approach be-
ween cardiologists and primary care providers may improve
utcomes for patients with CAD. Other studies evaluating
collaborative approach involving cardiologists have also
emonstrated better guideline concordance and outcomes
or conditions such as heart failure and dyslipidemia (32–
4). For example, Ryan et al. (33) demonstrated better
yslipidemia care through a multidisciplinary effort lead by
cardiologist with assistance from an advanced practice
urse. Patients underwent an intensive assessment and
reatment program with frequently scheduled visits, sug-
g
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Cardiology Management and Secondary Prevention May 5, 2004:1517–23esting that intensity of therapy may be an important
omponent for improving risk factor control. Future studies
hould attempt to identify the potential mechanisms
hereby specialty care results in improved outcomes. Such
actors could be studied prospectively to determine if im-
lementation results in improved morbidity, mortality, and
uality of life outcomes for patients with a wide spectrum of
ardiovascular diseases.
There are several potential explanations for the higher
roportion of cardiology involvement for patients achieving
uideline recommendations for LDL cholesterol and BP.
ardiologists may have more up-to-date and detailed
nowledge of the evidence supporting certain therapies. In
survey of cardiologists, internists, and family practitioners
bout four treatments demonstrated to have improved
urvival after AMI, cardiologists believed more strongly in
he results and were more likely to prescribe thrombolytics,
spirin, and beta-blockers (35).
In addition, cardiologists have a narrower focus in their
linical practice and can defer the care of non-cardiovascular
onditions to primary care providers. In our cohort, patients
ad an average of three co-morbidities in addition to CAD
nd were prescribed an average of 11 medications. Primary
are providers are, thus, faced with the management of a
arger number of conditions, where they have to weigh the
isks and benefits of prescribing additional medications or
djusting current medications with the potential for side
ffects that occur with polypharmacy or higher doses of
edications (36). Furthermore, primary care physicians
ften experience “tyranny of the urgent,” where the acute
ymptoms and concerns of patients crowd out the less
rgent need to bring chronic illness (e.g., hypertension and
yperlipidemia) under optimal management (37).
Although a larger proportion of patients with cardiology
nvolvement met secondary prevention guideline recom-
endations, overall rates of LDL cholesterol and BP
ontrol were low regardless of specialty involvement in this
tudy, 56.8% and 38.5%, respectively. Prior studies evaluat-
ng treatment of LDL cholesterol in secondary prevention
ave also noted low rates of guideline concordance (5,6).
lthough studies on hypertension treatment patterns have
ot focused specifically on CAD patients who have stricter
reatment goals, these studies have also found similarly low
ates of guideline adherence (7–9). Together, these studies
ighlight an urgent need to improve secondary prevention
ractice patterns because patients with preexisting CAD
ave a higher risk for recurrent cardiac events.
There are several potential limitations to this study.
lthough the database included complete laboratory, phar-
acy records, and visit histories from all Pacific Northwest
A facilities, information from outside the VA system were
ot available. However, given an average of eight clinic visits
er patient during the study period, it is likely that we have
aptured a significant proportion of all health care utiliza-
ion by these patients. Also, we defined the measurement
eriod for LDL cholesterol as the 15 months before thendex date, but patients could have been referred to cardi-
logy after this time period, resulting in misclassification
ias. This misclassification, however, would tend to bias the
esults towards the null. Next, we did not have reliable data
n medication doses. One possible explanation for the
nding of the study is that cardiology involvement patients
ere prescribed higher doses of medications. For example,
lthough a similar proportion of patients with and without
ardiology involvement received statin drugs, a higher pro-
ortion of cardiology involvement patients achieved LDL
100 mg/dl. Future studies should evaluate whether inten-
ity of drug therapy is a principal mechanism for the
ifferential outcomes.
Next, this was an observational study with significant
ifferences between patients with and without cardiology
nvolvement. The cardiology involvement patients were
icker at baseline with a heavier burden of co-morbidities.
owever, this disproportionate disease burden would bias
he results against cardiology involvement patients, and, if
nything, we may have underestimated the magnitude of
ssociation between cardiology involvement and improved
econdary prevention measures. Finally, although LDL
holesterol and BP levels are surrogate outcomes, they are
trongly linked to cardiovascular morbidity and mortality.
arge population-based studies have demonstrated signifi-
ant declines in cardiovascular events with even small
eductions in cholesterol or BP (21,24).
In conclusion, we found that cardiology involvement in
mbulatory care is associated with improved lipid and
ypertension control among CAD patients. However, sig-
ificant opportunity for improvement in the treatment of
econdary prevention measures remains for CAD patients,
rrespective of physician specialty. A collaborative approach
etween cardiologists and primary care providers may im-
rove outcomes for CAD patients. Future investigations
hould address specific mechanisms, such as intensity of
herapy that may explain the differences in outcomes noted
n this study.
eprint requests and correspondence: Dr. P. Michael Ho, 1055
lermont Street (111B), Denver, Colorado 80220. E-mail:
ichael.ho@uchsc.edu.
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